Compare CALX & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALX | TFX |
|---|---|---|
| Founded | 1999 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.8B |
| IPO Year | 2010 | N/A |
| Metric | CALX | TFX |
|---|---|---|
| Price | $53.82 | $120.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 10 |
| Target Price | $77.75 | ★ $134.88 |
| AVG Volume (30 Days) | ★ 692.8K | 586.6K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 1.13% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $933,685,000.00 | ★ $3,189,988,000.00 |
| Revenue This Year | $19.95 | $9.90 |
| Revenue Next Year | $12.89 | $10.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.89 | ★ 5.42 |
| 52 Week Low | $28.61 | $102.58 |
| 52 Week High | $71.22 | $188.87 |
| Indicator | CALX | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 35.55 | 58.30 |
| Support Level | $53.31 | $113.62 |
| Resistance Level | $54.81 | $117.14 |
| Average True Range (ATR) | 1.74 | 3.76 |
| MACD | -0.19 | 1.74 |
| Stochastic Oscillator | 31.08 | 98.64 |
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.